Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML

Abstract: Despite the use of FMS-like tyrosine kinase 3 (FLT3) inhibitors, outcomes for patients with FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) remain suboptimal because of high rates of relapse. We evaluated the safety and efficacy of the combination of daunorubicin, cytarabine (DA), gemt...

Descripció completa

Dades bibliogràfiques

Autors principals:	Nigel Russell, Jad Othman, Oliver Cumming, Abin Thomas, Aditya Tedjaseputra, Nicola Potter, Jelena Jovanovic, Amanda Gilkes, Leona Batten, Joanna Canham, Emily Hinson, Manohursingh Runglall, Phoebe Aucken, Panos Kottaridis, Jamie Cavenagh, Claire Arnold, Sylvie Freeman, Mike Dennis, Steven Knapper, Richard Dillon
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-12-01
Col·lecció:	Blood Advances
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2473952925005956
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!